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Abstract Measles was successfully eradicated in the Pan-
American Health Region in 2002. However, maintenance
of elimination in parts of Africa, Europe, the USA, and
other regions is proving difficult, despite apparently high
vaccine coverage. This may be due to the different age
structure in developed and developing populations, as well
as to differences in the duration of maternal immunity. We
explore the interaction between maternal immunity and
age structure and quantify the resulting immunity gap
between vaccine coverage and population immunity; we
use this immunity gap as a novel metric of vaccine pro-
gram success as it highlights the difference between actual
and estimated immunity. We find that, for some combina-
tions of maternal immunity and age structure, the accepted
herd immunity threshold is not maintainable with a single-
dose vaccine strategy for any combination of target age
and coverage. In all cases, the herd immunity threshold is
more difficult to maintain in a population with developing
age structure. True population immunity is always
improved if the target age at vaccination is chosen for
the specific combination of maternal immunity and age
structure.
Keywords Context-dependent management . Disease
elimination .Maternal immunity .Measles . Vaccination
Introduction
Great progress has been made towards worldwide measles
eradication, yet it still remains an elusive objective, as endem-
ic disease persists in some places, and is reintroduced to others
where it was long absent. One aspect of the measles problem
is maintenance of elimination; the disease has begun to re-
emerge in places where it was thought to be eliminated. Mea-
sles was officially eliminated from the USA in 2000 and the
Pan-American Health region (PAHO region) in 2002
(Castillo-Solórzano et al. 2011a, b), and, despite recent out-
breaks, endemic transmission has not reemerged. However,
other countries have not been as successful at maintaining
elimination. Europe has seen recent increases in transmission,
despite promising improvements in the early 2000s (Morbidy
and Mortality Weekly Report 2011), including places like
Germany (Roggendorf et al. 2010; van Treeck 2006) and
France (Parent du Châtelet et al. 2010). Recent outbreaks have
occurred in parts of southern Africa where measles was pre-
viously reduced near the point of elimination (Shibeshi et al.
2014). Additionally, despite the disease officially remaining
eliminated in the USA, there have been recent outbreaks that
cast doubt on the actual population immunity to measles in the
USA (Parker and Staggs 2006; Sugerman et al. 2010).
With measles, as with any other directly transmissible, im-
munizing infection, there is some threshold level of immunity
in the population, called the herd immunity threshold, beyond
which the disease cannot invade (Anderson and May 1991).
The goal of measles vaccination programs is to achieve and
maintain a sufficiently large immunized population that this
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threshold will be met, and measles will be locally eradicated
and unable to reinvade. The conventional wisdom for measles
is that this threshold level of immunity is 90–95 % (Hall and
Jolley 2011; Moss and Griffin 2006).
Measles vaccination programs since the 2002 PAHO elim-
ination are typically composed of multiple strategies for vac-
cine distribution (Danet and Fermon 2013; Koehlmoos et al.
2011). Here, we consider routine immunizations (RIs), in
which children of specific ages are vaccinated during clinic
visits (Bauch et al. 2009). RIs, in combination with other types
of vaccination campaigns, were used to effectively eradicate
measles in the Americas by 2002 (Castillo-Solorzano et al.
2011a, b). RIs are targeted at a specific age; the World Health
Organization recommendsmeasles vaccination between 9 and
12 months of age (WHO 2012).
Trans-placentally acquired maternal immunity temporarily
protects infants born to immune mothers, but interferes with
vaccine efficacy (Cutts et al. 1995; Gans et al. 2001). Vaccines
administered before this maternal immunity wanes will be
ineffective, but otherwise, there is minimal disadvantage to
vaccinating children as early as possible. Therefore, there is
a window of susceptibility between the waning of maternal
immunity and the average age of infection during which vac-
cination is likely to be effective and prophylactic in most
children (McLean and Anderson 1988a, b). The optimal age
of vaccination will fall within this age window, where the
lower end is determined by acquired maternal immunity
(Moss and Griffin 2006; McLean and Anderson 1988a, b),
and the upper end is classically considered to be determined
by local disease incidence (McLean and Anderson 1988a, b).
There is uncertainty in the literature about when, on aver-
age, maternal immunity wanes in any specific population.
Some evidence suggests that vaccine-derived maternal immu-
nity wanes earlier than naturally derived maternal immunity
(that is, maternal immunity from women who have been in-
fected with measles) (Leuridan et al. 2010), but the magnitude
of this difference and the effect it may have on the optimal age
at which to vaccinate is unclear. Additionally, the mother’s
health (Scott et al. 2005) as well as local nutrition and breast
feeding practices have been shown to affect the rate of waning
of maternal immunity and are difficult to know precisely
(Cáceres et al. 2000). What limited evidence we have available
suggests that the rate at which maternal immunity wanes varies
from country to country (McLean and Anderson 1988a, b).
In places where measles is endemic, children may become
infected and therefore become naturally resistant before the
age at first vaccination. Thus, vaccines administered too late
fail to prevent disease and may be considered as “wasted”
doses—doses administered to a person already immune. It is
classically understood that, as disease incidence declines, av-
erage age of infection increases (Roggendorf et al. 2010), thus
increasing the upper age limit on the window of infant sus-
ceptibility. In these settings, a common policy is to increase
the target age of routine immunizations so that a greater
proportion of infants will have lost maternal immunity,
and each dose is more likely to be more effective (Christie and
Gay 2011).
However, we have seen unexpected outbreaks in countries
with what was thought to be good measles control, such as the
2009 epidemic in Burkina Faso (Kidd et al. 2012) and the
2010 epidemic in Malawi (Minetti et al. 2013a, b). These
countries had otherwise low disease incidence and high rou-
tine coverage. However, these unexpected epidemics indicate
that, despite the lowmeasles incidence, there was a substantial
susceptible pool. The interaction between vaccine effective-
ness, maternal immunity, and the chosen age target for routine
immunization may have contributed to the rapid build-up of
this susceptible pool and the underestimation of outbreak risk.
Differences in age structure could also contribute to ob-
served differences in population immunity resulting from sim-
ilarly targeted RIs. Notably, the proportion of the population in
the Americas that is <1 year old is much smaller than the pro-
portion of the African population that is <1 year old. As such,
the number of children in the susceptible window in Africa will
make up a relatively large proportion of the population andmay
suggest the need for a different target age for routine immuni-
zation. Consequently, the upper end of the infant susceptibility
window may also be determined by the age structure of the
region, rather than solely by disease incidence. Importantly, if
the target age of vaccination is not tailored to average local
immunity and age structure, the proportion of infants no longer
maternally immune but not yet vaccinated might be too large
for herd immunity to be achievable (Fig. 1a). In essence, if more
than 5 % of the population is in the susceptible window be-
tween waning of maternal immunity and vaccination, a 95 %
population immunity level will be unachievable.
The existence of this window of susceptibility (Fig. 1)
means that population immunity will always be less than or
equal to routine immunization coverage in disease-free set-
tings. That is, some doses are administered to infants who still
retain their maternal antibodies, and some susceptible infants
are not yet eligible for the vaccination. Thus, for any combi-
nation of age target, age distribution, and waning rate, we can
characterize the immunity gap between coverage and popula-
tion immunity; this immunity gap tells us the amount by
which population immunity falls short of coverage.
In this paper, we develop a discrete-time age-structured
population model for the distribution of immunity in a
disease-free population and analyze the equilibrial states of
this model. We analyze the size and distribution of the cross-
hatched regions in Fig. 1, which show the proportion of the
population not covered by either maternal immunity or vacci-
nation. We use this analysis to assess the relative size and age
distribution of the susceptible population resulting from a va-
riety of vaccine plans, specified by target age and coverage,
and the effect of these plans on population immunity. We also
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calculate the immunity gap between population immunity and
coverage for each of these vaccine plans. We then evaluate
these vaccine plans (specific combinations of target vaccina-
tion age and planned coverage) for a range of age distributions
to quantify the impact of age structure on vaccine program
success. We then suggest some methods for selecting among
a range of vaccine plans where herd immunity is equally
achievable or unachievable.
Materials and methods
We developed an age-structured model for a human popula-
tion, using 131 age classes. Age classes are monthly, up to
5 years old, and then are yearly until 75 years old, when we
assume individuals are removed from the population. The rel-
ative size of these age classes is determined by a specified age
structure. We explored two base age structures—a concave
one, representing an idealized developed population, as in the
USA, and a convex one, representing an idealized developing
population, as in Sub-Saharan Africa (see Fig. S1 in Supple-
mental Material). Throughout this paper, we use “developing”
and “developed” to refer solely to the age structure of the
region, not their economic development. We also consider
the effect of a range of intermediate age structures, based on
a weighted (α) average of these two base age structures.
Each of these age classes are then divided into one of three
immune classes—maternally immune, susceptible, or vacci-
nated. In this study, we omit the naturally immune classes, as
we conduct a steady-state analysis under the assumption of
long-term disease absence, as might be the case in most of the
USA.We then quantify the relative size and age distribution of
these classes, paying special attention to the susceptible class,
as that is the class of interest for population immunity; the
Fig. 1 Two sample age
distributions of immunity within a
population. The dark gray region
is the portion still maternally
immune, the pale gray region is
the vaccinated proportion, and the
hatched region is the proportion
that remains susceptible. The x-
axis is shown on a log scale, so
the total hatched regions in a and
b are of similar area. In a, the
vaccine is administered too late,
and too many infants remain
susceptible. In b, the vaccine is
administered too early, so too few
doses are effective. Both of these
figures use a developing
population age structure assuming
6-month maternal immunity
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susceptible class can make up no more than 5 % of the pop-
ulation if we are to maintain herd immunity.
To divide these age classes into the immune classes, we first
calculate the proportion of individualswho are bornwithmaternal
immunity (Eq. 1). Then, accounting for maternal immunity wan-
ing at a specified rate, we calculate the proportion of individuals in
each older age class. Once we know what proportion of individ-
uals in each age class is maternally immune, we can calculate
effective vaccine cover from a specified target age and coverage,
given that maternally immune individuals cannot be successfully
immunized. From there, we assume that the proportion of vacci-
nated individuals in each subsequent age class remains the same.
We assume that the remainder of the population (that is, those not
maternally immune or vaccinated) is susceptible.
Vaccines are administered at a given age, t, with a given cov-
erage, C; this combination of specifications is termed the vaccine
plan. The proportion that are successfully immunized is a propor-
tion equal to the coverage,C, of the proportion of individuals that
are not maternally immune in the target age class, t. We assume
that these two proportions are independent, as a proportion of the
vaccinated population is still maternally immune and so is vacci-
nated but does not achieve vaccine-derived immunity—that is, is
not considered successfully vaccinated. Each subsequent age
class has the same proportion of successfully vaccinated individ-
uals as the first vaccinated age class, t, but loses some immune
individuals as maternal immunity continues to wane.
The probability that any individual is born with maternal im-
munity depends on the equilibrium state of a generational model.
The probability that an individual is born maternally immune in
generation T, pMT, is equal to the probability that his/her mother
was successfully vaccinated in the previous generation, VT−1.
This, in turn, is dependent on the vaccine coverage, C, and the
probability that the mother was no longer maternally immune
when the vaccine was administered at age t, so that:







Here, ω is the average age where maternal immunity
wanes. Assuming that there has been no change in vaccine
policy or maternal immunity between generations, the steady-
state proportion of infants born with maternal immunity, pM
(where pM ¼ pMT ¼ pM T−1ð Þ), is found by solving the
resulting equation:












Notably, this proportion goes up with coverage, but satu-
rates at some level dependent on the average age of maternal
immunity waning and the age at vaccination.
For each successive age class, we then find the proportion of
individuals that remain maternally immune, based on one of
two exponential decay functions with an average age of waning
of either 3 or 6 months. We chose these average ages because
most estimates in the literature fall within that range (Cáceres
et al. 2000; Waaijenborg et al. 2013). That is, each successive
age class has ω−1ω times as many maternally immune individuals
as the previous class, where ω is either 3 or 6 (see Fig. S2 in
Supplemental Material). Maternal immunity continues to
wane in this way until the 5-year age class, when we assume
that no individuals are maternally immune any longer.
The proportion of each age class left susceptible is simply
the proportion neither maternally immune nor immunized.
From this model, we have an age distribution of susceptibility,
with different numbers of susceptible individuals in each age
class. We first calculate the total proportion immune achieved
by any specific vaccine plan given by a target age and cover-
age. We then examine the resulting age distribution of suscep-
tibility, and how that varies with coverage. We also examine
the immunity gap between programmatic vaccine coverage
and achieved population immunity, with the idea that this
immunity gap might provide a means of discriminating be-
tween apparently equivalent vaccine plans. Finally, we assess
the dependence of this vaccine program success on age struc-
ture, both in how age structure can affect the recommended
vaccine plan and how the success of a specific vaccine plan
depends significantly on age structure alone.
Results
We first develop contours for the maintainable population im-
munity for a given age structure and maternal immunity du-
ration, under a specific vaccine plan comprising of a specified
target age (in months) and coverage (Fig. 2). For a developing
age structure with maternal immunity waning at 6 months, the
commonly quoted herd immunity threshold of 95 % is
unachievable, no matter when children are vaccinated and
what coverage is achieved (Fig. 2a). However, if vaccination
is targeted at the older age classes (12 +months) and achieves
high coverage, then over 90 % of the population will be im-
mune. When maternal immunity in a developing age structure
is assumed to wane at 3 months, the herd immunity threshold
is achievable, but only for extraordinarily high coverage and
over a limited age range for vaccination (Fig. 2b).
In comparison, it is relatively easy to achieve the herd im-
munity threshold with a developed age structure. With mater-
nal immunity waning at 6 months, the herd immunity thresh-
old is achievable if vaccination occurs at an older age and with
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high coverage (Fig. 2c). Notably, this successful age range is
strictly older than the age range successful in a developing
region with maternal immunity waning at 3 months
(Fig. 2b). If maternal immunity wanes at 3 months on average,
then the herd immunity threshold is achievable with high cov-
erage at a wide range of ages (Fig. 2d). Taking the difference
between the two developed surfaces (Fig. 3a) shows that the
average age at which maternal immunity wanes makes the
largest difference in population immunity when vaccination
happens at a young age and with high coverage. The general
shape of this difference in response to waning maternal im-
munity is the same regardless of the underlying age structure.
Comparing the results from the developed and the developing
age structures shows that the shape of the differences due to
underlying population age structure (Fig. 3b) is similar no
matter the rate at which maternal immunity wanes, although
the maximum magnitude of the difference varies (the shape of
the immunity gap between coverage and population immunity
is not the same, as shown in Fig. S4 in Supplemental
Material).
Fig. 2 a, b Maintainable population immunity for maternal immunity
waning at 6 and 3 months, respectively, in a region with a developing age
structure. c, dMaintainable population immunity for maternal immunity
waning at 6 and 3 months, respectively, in a region with developed age
structure. Strategies that meet the 95 % threshold are shown in black;
those that meet the 90 % threshold are shown in gray
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We quantify the impact of age structure on vaccine pro-
gram success by considering a range of age structures, which
are linear composites of the developing and developed age
structures according to some weight, α. We use α to represent
the proportional weight of the developing age structure—for
example, when α is 0.25, this means that we took a weighted
Fig. 3 a The difference in
population immunity due to
differences in maternal immunity
(i.e., the difference between
Fig. 2c and d). b Difference in
population immunity for maternal
immunity waning at 3 months
between regions with a developed
and developing age structure (i.e.,
the difference between Fig. 2b
and d). Note that the target ages of
vaccination which minimize the
difference due to a difference in
maternal immunity are where the
difference due to a difference in
age structure starts to increase
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average of the two age structures, with a 25 % weight on the
developing age structure and a 75 % weight on the developed
age structure. When α is 0, the age structure is precisely the
developed age structure, and when α is 1, the age structure is
precisely the developing age structure. We find that, even
when vaccinating to achieve maximum population immunity
given a specific age structure (Fig. 4a), the achieved popula-
tion immunity continually decreases as the age structure be-
comes more and more similar to the purely developing one.
With maternal immunity waning at 6 months, the 95% thresh-
old is entirely unachievable once more than 60 % of the age
structure is of the developing form. The situation is even
worse if the same vaccine plan (i.e., same coverage and target
age) is applied across all age structures, especially if the one
that works best for the developing age structure is chosen
(Fig. 4b).
Population immunity is always less than vaccine coverage
(to see how they relate, see Fig. S3 in Supplemental Material),
but the difference depends on the specific vaccine policy and
population structure. We show the immunity gap for several
target ages, which are sufficient for herd immunity in a devel-
oping region, where the target age that minimizes the immu-
nity gap changes depending on vaccine coverage (Fig. 5).
Notably, the shape of these different curves changes depend-
ing on the target age of vaccination, as the source of the im-
munity gap (age structure or maternal immunity) changes de-
pending on target age. This change in shape means that the
target age that minimizes the immunity gap changes with re-
spect to coverage. In Fig. 5a, for coverages below around
67 % (indicated by the lighter vertical line), it is best (in terms
of minimizing the immunity gap) to vaccinate at 10 months of
age, as low coverage will mean low levels of maternal immu-
nity. For higher coverages, it is best to vaccinate at 12 months.
At around 92 % coverage—indicated by the darker vertical
line in Fig. 5a and the only vertical line in Fig. 5b—the for-
merly optimal target age becomes dramatically worse due to
Fig. 4 The maintainable population immunity for a range of age
structures. When α is 0, the age structure is the idealized developed
one. When α is 1, the age structure is the idealized developing one. a
As the age structure shifts from developed to developing, the maximum
maintainable proportion immune continuously declines. Notably, the
proportion immune for long maternal immunity is lower than that for
short maternal immunity despite both being the specific maxima for
that maternal immunity function. That is, the optimal vaccine policy for
long maternal immunity is always less successful than the optimal for
short maternal immunity. b The achievable proportion immune when
vaccinating at 12 months. With a developed age structure and short
maternal immunity, this is a successful vaccine policy. However, as the
age structure shifts towards the purely developing one, the success of the
vaccine policy continually declines. With long maternal immunity,
maintainable immunity is similarly low everywhere, but still worse on a
developing age structure
Theor Ecol (2015) 8:261–271 267
the nonlinear interaction with maternal immunity, with the im-
munity gap exceeding that of all but the very oldest target ages.
Discussion
Our work shows that herd immunity may not be maintainable
with a single-dose routine vaccine plan, even administered
optimally, depending on the specific age structure and mater-
nal immunity of the region. Fortunately, strategies for the
maintenance of measles elimination commonly include a sec-
ond dose. However, even in the context of a second-dose
vaccine plan, it does not make sense to administer the first
dose of a two-dose vaccine strategy ineffectively, with the
hope that the second dose will make up for failings in the first,
especially if the result is a large susceptible population that is
too young to be caught by a second-dose vaccine strategy at
all. Optimizing the first dose is beneficial in all cases. Our
results suggest ways that we can maximize the impact of the
first dose to improve population immunity by specifically
targeting a vaccine program to the local context, specifically
the demography and maternal immunity levels of the target
population.
In principle, herd immunity is maintainable in all cases
except when vaccinating in a population with a developing
age structure and long maternal immunity (Fig. 2a). However,
herd immunity is maintainable for a wider range of coverage
and ages when vaccinating given a developed age structure
(Fig. 2c,d). Notably, the range of target ages where herd im-
munity is maintainable in a developed region is much older
than the age range where herd immunity is maintainable in a
developing region, if it is maintainable at all in a developing
region.
With a developing age structure, where the average age is
fairly young, more children fall below the age of first vacci-
nation, and herd immunity is more difficult to maintain. It is
especially difficult if the choice of vaccine plan is based on the
recommended strategy for a developed age structure, where
the average age is much older (Fig. 4b). This demonstrates the
importance of context-dependent vaccination planning. Pop-
ulation immunity improves when a vaccine plan optimized to
the local age structure and maternal immunity function is cho-
sen (Fig. 4a), so that the difficulty imposed by the age struc-
ture is effectively minimized. Interestingly, the age at vacci-
nation that maximizes population immunity in a developing
region is often younger than that which maximizes immunity
in a developed region. That is, the luxury to vaccinate older
individuals to minimize doses rendered ineffective by mater-
nal immunity is affordable when vaccinating in a developed
region, but age structure forces the vaccination of younger
individuals when vaccinating in a developing region. Notably,
reducing the age of first vaccination is a strategy not generally
considered when making and implementing current vaccine
policy.
Context-dependent vaccination planning may also be use-
ful at a finer spatial scale. Vaccine program success in Africa is
relatively patchy, with some countries having only sporadic
outbreaks that suggest they are near elimination, while others
still have regular seasonal outbreaks (Minetti et al. 2013a, b;
Ferrari et al. 2008). These regional differences in vaccine pro-
gram success may be due to differences in logistic effective-
ness, but are likely also impacted by the interaction of mater-
nal immunity and age structure. Just as regions with
Fig. 5 These panels show the immunity gap—that is, the difference
between vaccine coverage and population immunity—for a variety of
target ages and coverages. Here, we are comparing these vaccine
schedules in a developing population with 3-month maternal immunity.
a At high coverage, all of these vaccine schedules could achieve herd
immunity. However, as maternal immunity is less significant at older
ages, it has a different effect on the immunity gap at the different ages.
Notably, the immunity gap line when vaccinating at the youngest age
with high coverage is significantly curved. b Focusing on the immunity
gap at coverages that might be maintained in regions with measles elim-
ination, it is clear that 12 months is the best age to vaccinate at all of these
coverages in a region with this age structure and maternal immunity
decay. However, whether it would be better to miss the target age by
vaccinating a little too young (10 months) or a little too old (14 months)
depends on coverage, with vaccinating younger ages still being worse at
high coverages
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developing age structures, such as Africa, are different from
regions with developed age structures, such as the Americas,
different regions within Africa are different from each other
with regard to age structure and also, potentially, the duration
of maternal immunity. A context-dependent management
strategy that takes into account local patterns in immunity
and age structure and evaluates their relative significance is
necessary in this case.
We introduce a new measure of program success called the
immunity gap and examine the effect of changing target age or
changing population age structure and maternal immunity on
the relationship between coverage and the immunity gap. In
some ways, the immunity gap represents “wasted” doses—
that is, the difference between population vaccine coverage
and population immunity achieved. Regardless of vaccine
plan or population, the immunity gap always increases as
coverage increases. This is, in some ways, a numerical repre-
sentation of the “last mile” problem (Klepac et al. 2013)—as
measles control improves, the cost per case prevented in-
creases. However, the way this the immunity gap scales with
coverage varies depending on the source of the immunity gap.
If vaccines are administered too early (Fig. 5), the immu-
nity gap varies nonlinearly (almost exponentially) with cover-
age. This is a signature of the maternal immunity function on
population immunity. If the vaccine is administered later, or to
a population with shorter maternal immunity, the immunity
gap scales more linearly with coverage. By looking at these
together, general recommendations can be made. If the source
of this immunity gap is interference with maternal immunity,
vaccines should be administered at older ages. If the source is
the interaction with age structure, vaccines should be admin-
istered at younger ages. The immunity gap could provide a
novel way to select between apparently equal vaccine plans.
Choosing a vaccine plan to minimize the immunity gap given
information about local age structure, maternal immunity
levels, and achievable coverage would also maximize the pro-
portional immunity conferred per dose administered.
The immunity gap is not the only means of selecting be-
tween vaccine plans. In cases where increasing the age of
vaccination reduces the immunity gap, this change in age
targets may increase the potential mortality associated with
an epidemic by increasing the proportion of susceptible indi-
viduals who are very young. Targeting younger children for
vaccination may increase the immunity gap nonlinearly, but
could minimize loss of life, as a larger proportion of suscepti-
ble individuals would fall in the less at-risk age classes. When
coverage is low, the immunity gap is small and the majority of
susceptible individuals are in the oldest age classes. As cov-
erage increases, the immunity gap increases and the propor-
tion of susceptible individuals below the age of vaccination
increases, although the absolute number may not. The magni-
tude of this shift depends on the target age of vaccination and
the age distribution and maternal immunity function of the
population. Again, these younger children are the individuals
that are most likely to die during an epidemic (Wolfson et al.
2009).
An additional utility of the immunity gap measure (Fig. 5)
is that using vaccine coverage as a proxy for population im-
munity may lead to a severe underestimation of disease risk,
and the size of this underestimate is context dependent. This
may explain some of the patterns in measles reemergence that
we see in places with what was thought to be good vaccine
coverage, such as Malawi and Germany. Malawi had reason-
ably good measles control, having seen a period of local elim-
ination of disease. However, in 2010, there was a devastating
outbreak, with the age distribution of cases being much older
than expected (Minetti et al. 2013a, b). At the time, Malawi
was officially administering a first dose of the measles vaccine
to infants between the ages of 9 and 11 months, with a second
dose comprising of a supplemental immunization campaign
targeting individuals <5 years old. On the other hand, Germa-
ny has struggled to maintain herd immunity to measles for a
while, with frequent outbreaks. The age distribution of some
of these outbreaks (Siedler et al. 2011) is older than typically
seen in a measles outbreak. In Germany, the first dose was
classically administered at 12 months, with the second dose
coming between 4 and 6 years of age. In 2001, Germany
changed its guidelines, expanding the window for first dose
administration and lowering the age of the second dose. In
both cases, coverage was thought to be good, but outbreaks
occurred. Thus, while administrative coverage may have been
at, or above, the programmatic target, the combination of age
distribution and waning of immunity may have resulted in
subcritical immunity.
Our work does not include population heterogeneity, age-
specific contact patterns, or age-specific force of infection.
Such processes are certainly relevant for more complex dy-
namical analyses of measles incidence. We omit them, in part,
because our work is an intentionally simple analysis to high-
light the importance of an underconsidered tradeoff between
age structure and maternal immunity. Additionally, single-
dose vaccine plans are not commonly implemented intention-
ally (Hall and Jolley 2011). There is evidence for the existence
of remote locales with low disease incidence and low second-
dose coverage (Minetti et al. 2013a, b), but most countries
officially give a second dose of the measles vaccine, even
though the second dose may not be administered at the rec-
ommended ages or at the ages with the largest remaining sus-
ceptible populations (Clark and Sanderson 2009). This re-
search could provide a means to optimize vaccine policy for
such locales, as well as other locales where second-dose cov-
erage is patchy or otherwise uncertain, though future work
incorporating a second dose would also be informative.
This work presents an equilibrial analysis of this disease
system, meant to supplement existing dynamical work in an
intuitive way. Future work could include additional aspects of
Theor Ecol (2015) 8:261–271 269
vaccine program complexity, including target age ranges and a
second-dose vaccine strategy, as well as disease dynamics.
Nonetheless, this work has some interesting implications. As
a larger proportion of any population is below the age of
vaccination, herd immunity becomes increasingly difficult to
maintain—that is, if a population has a relatively large infant
population, herd immunity to measles will be difficult, if not
impossible, to maintain with a single-dose vaccine plan. Pop-
ulation structure also interacts with the waning of maternal
immunity in ways that can mislead us into thinking that pop-
ulation immunity is better than it really is. However, our work
suggests the possibility of improving local disease control,
despite obvious difficulties, by taking specific context-
dependent factors into account (Hall and Jolley 2011). Our
model could be adapted to fit any specified age structure and
maternally derived immunity waning function and then used
to make a recommendation that minimizes the immunity gap
given an estimated coverage. These results are only compli-
cated if maternal immunity lasts too long to effectively vacci-
nate any earlier. However, given a heavily youth-weighted age
structure, vaccinating earlier may be beneficial, as a second-
dose vaccine strategywill be better at catching those for whom
the vaccine was not effective.
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